Global Information
회사소개 | 문의

골전이 : 파이프라인 리뷰

Bone Metastasis - Pipeline Review, H2 2018

리서치사 Global Markets Direct
발행일 2018년 10월 상품 코드 251586
페이지 정보 영문 109 Pages
가격
US $ 2,000 ₩ 2,278,800 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,557,600 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 6,836,400 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


골전이 : 파이프라인 리뷰 Bone Metastasis - Pipeline Review, H2 2018
발행일 : 2018년 10월 페이지 정보 : 영문 109 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

골전이(뼈전이)란 암세포가 원발 부위에서 뼈로 전이하여 발생하는 것으로, 뼈 통증, 골절, 요실금, 변실금, 다리 탈진감 등의 징후 및 증상이 있습니다. 유방암, 전립선암, 폐암, 갑상선암, 신장암 등의 특정 암 등이 소인이며, 치료법에는 화학요법, 수술, 방사선 치료 등이 있습니다.

세계의 골전이(Bone Metastasis) 치료제 파이프라인에 대해 분석했으며, 현재 개발 파이프라인 상황 및 최신 동향, 약제 개요, 주요 기업 및 개발중인 제품 리뷰 등을 정리하여 전해드립니다.

목차

서론

  • 분석 범위

골전이 개요

치료제 개발

  • 골전이용 파이프라인 제품 : 개요
  • 기업별 파이프라인 제품
  • 대학/연구기관별 파이프라인 제품
  • 기업에서 개발중인 제품
  • 대학/연구기관에서 개발중인 제품

치료제 평가

  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

골전이 : 치료제 개발 참여 기업

  • Ablynx NV
  • Amgen Inc
  • Amura Holdings Ltd
  • BiologicsMD Inc
  • ChemoCentryx Inc
  • Deciphera Pharmaceuticals LLC
  • Eli Lilly and Company
  • Leadiant Biosciences Inc
  • Lupin Ltd
  • Mirati Therapeutics Inc
  • Oncobiologics Inc
  • Oncodrone BV
  • OPKO Health Inc
  • Osteologix Holdings Plc
  • R Pharm
  • Redx Pharma Plc
  • Taiho Pharmaceutical Co Ltd
  • Terpenoid Therapeutics Inc

약제 개요

휴지중인 프로젝트

개발 중지 제품

제품 개발 마일스톤

  • 주목 뉴스 및 프레스 릴리스

부록

도표

LSH 17.06.12

List of Tables

  • Number of Products under Development for Bone Metastasis, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Stage and Target, H2 2018
  • Number of Products by Stage and Mechanism of Action, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Bone Metastasis - Pipeline by Ablynx NV, H2 2018
  • Bone Metastasis - Pipeline by Amgen Inc, H2 2018
  • Bone Metastasis - Pipeline by Bayer AG, H2 2018
  • Bone Metastasis - Pipeline by CSPC Pharmaceutical Group Limited, H2 2018
  • Bone Metastasis - Pipeline by Deciphera Pharmaceuticals LLC, H2 2018
  • Bone Metastasis - Pipeline by Eli Lilly and Co, H2 2018
  • Bone Metastasis - Pipeline by Lupin Ltd, H2 2018
  • Bone Metastasis - Pipeline by MabVax Therapeutics Holdings Inc, H2 2018
  • Bone Metastasis - Pipeline by Mirati Therapeutics Inc, H2 2018
  • Bone Metastasis - Pipeline by Oncobiologics Inc, H2 2018
  • Bone Metastasis - Pipeline by Oncodrone BV, H2 2018
  • Bone Metastasis - Pipeline by OPKO Health Inc, H2 2018
  • Bone Metastasis - Pipeline by Qilu Pharmaceutical Co Ltd, H2 2018
  • Bone Metastasis - Pipeline by R Pharm, H2 2018
  • Bone Metastasis - Pipeline by Reliance Life Sciences Pvt Ltd, H2 2018
  • Bone Metastasis - Pipeline by Serene LLC, H2 2018
  • Bone Metastasis - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2018
  • Bone Metastasis - Pipeline by Terpenoid Therapeutics Inc, H2 2018
  • Bone Metastasis - Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H2 2018
  • Bone Metastasis - Dormant Projects, H2 2018

List of Figures

  • Number of Products under Development for Bone Metastasis, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Top 10 Targets, H2 2018
  • Number of Products by Stage and Top 10 Targets, H2 2018
  • Number of Products by Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Routes of Administration, H2 2018
  • Number of Products by Stage and Routes of Administration, H2 2018
  • Number of Products by Molecule Types, H2 2018
  • Number of Products by Stage and Molecule Types, H2 2018

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bone Metastasis - Pipeline Review, H2 2018, provides an overview of the Bone Metastasis (Oncology) pipeline landscape.

Bone metastasis occurs when cancer cells spread from their original site to a bone. Signs and symptoms of bone metastasis include bone pain, broken bones, urinary incontinence, bowel incontinence and weakness in the legs. The predisposing factors include certain kinds of cancer (breast, prostate, lung, thyroid, and kidney cancers). Treatment options for bone metastasis are chemotherapy, surgery and radiation therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bone Metastasis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Bone Metastasis (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bone Metastasis (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bone Metastasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 2, 7, 1 and 17 respectively. Similarly, the Universities portfolio in Preclinical, Discovery and Unknown stages comprises 5, 1 and 1 molecules, respectively.

Bone Metastasis (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bone Metastasis (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Bone Metastasis (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bone Metastasis (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bone Metastasis (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bone Metastasis (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bone Metastasis (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bone Metastasis (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Bone Metastasis - Overview
  • Bone Metastasis - Therapeutics Development
  • Bone Metastasis - Therapeutics Assessment
  • Bone Metastasis - Companies Involved in Therapeutics Development
  • Bone Metastasis - Drug Profiles
  • Bone Metastasis - Dormant Projects
  • Bone Metastasis - Discontinued Products
  • Bone Metastasis - Product Development Milestones
  • Appendix
Back to Top
전화 문의
이용안내
 
BCC Research